National Institute

ActiveState Enables Software Vendors to Comply with White House Orders for Securing the Software Supply Chain

Retrieved on: 
Thursday, November 10, 2022
WH, White House, Risk, Catalog, Organization, Compliance, ActiveState, Time, National Institute, Software, National Institute of Standards and Technology, White, SLSA, Artifact, NIST, Online shopping, BC, Technology

VANCOUVER, BC, Nov. 10, 2022 /PRNewswire/ -- Today, ActiveState announced the availability of open source software attestations, making it the first open source software platform to deliver this essential component of software supply chain security. The ability to obtain self-attestation for all third-party software, as well as producing a software bill of materials (SBOM), is part of sweeping guidance from the National Institute of Standards and Technology (NIST) that has been adopted by the White House. According to a recent White House order, all critical software that touches government data or systems in any way must be compliant with these new security standards no later than June 12, 2023. All software must adhere to these strict standards no later than September 14, 2023.

Key Points: 
  • VANCOUVER, BC, Nov. 10, 2022 /PRNewswire/ -- Today, ActiveState announced the availability of open source software attestations, making it the first open source software platform to deliver this essential component of software supply chain security.
  • ActiveState builds and fervently maintains a curated catalog of trusted artifacts that meets the requirements for Supply Chain Levels for Software Artifacts ( SLSA ) level 4, including software bill of materials (SBOM) and attestations, to proactively secure customers' software supply chains.
  • Click to tweet: ActiveState adds open source attestations, alongside its existing software bill of materials (SBOM) capabilities, to enable customers to comply with White House orders regarding software supply chain security.
  • Loreli Cadapan, Vice President, Product, ActiveState, said: "We believe the White House order signals a larger trend that will soon become industry standard.

Astec Appoints New Members to Board of Directors

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Mining, Engineering, Cleveland State University, NYSE, Nasdaq, ASTE, Science policy, Regal Beloit, Aviation, Transport, GE Aviation, Financial compensation, Technology, Indian School of Business, Plant, Board, National Institutes of Technology, Computer science, Digital electronics, Bowling Green State University, Electronics, National Institute, BS, School, Company, Solution, GE, MBA, Wabtec, Bombardier Inc., Social media, Audit committee, CEO, General Electric, APAC, Retirement, GE Transportation, Management, Rock

CHATTANOOGA, Tenn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (Nasdaq: ASTE) announced the companys board of directors (the Board) elected Mr. Mark Gliebe and Mr. Nalin Jain, each a new independent director, effective as of November 10, 2022.

Key Points: 
  • CHATTANOOGA, Tenn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Astec Industries, Inc. (Nasdaq: ASTE) announced the companys board of directors (the Board) elected Mr. Mark Gliebe and Mr. Nalin Jain, each a new independent director, effective as of November 10, 2022.
  • The election of Mr. Gliebe and Mr. Jain increases the size of the Board to 12 directors, 11 of whom are independent directors.
  • Each of Mr. Gliebe and Mr. Jain will serve as a member of the Audit Committee of the Board.
  • William Gehl, Chairman of Astecs Board of Directors, said, We are pleased to welcome Mark and Nalin to the Board.

Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial

Retrieved on: 
Tuesday, November 8, 2022
Nicotine, GLOBE, Private Securities Litigation Reform Act, National, Health, Moyamoya disease, Adult, Nature, U.S. Securities and Exchange Commission, Food, Nasdaq, Smoking, Risk, Regulation of tobacco by the U.S. Food and Drug Administration, Research, NIH, Lung cancer, COVID-19, Brain, Transfusion-related acute lung injury, National Institute on Drug Abuse, Safety, Herbal cigarette, Smoker, Goal, National Institute, Reward, Clinical trial, TID, Tobacco smoking, Degenerative disease, Death, Security (finance), NIDA, FDA, Trial of the century, Pharmaceutical industry, Tobacco

ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes.

Key Points: 
  • ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes.
  • The earlier-than-expected completion of enrollment in the ORCA-V1 trial further elucidates the critical need for treatment options specific for nicotine vape users who are interested in quitting, stated John Bencich, Chief Executive Officer of Achieve.
  • Earlier this year Achieve announced positive, statistically significant results in its Phase 3 ORCA-2 clinical trial of cytisinicline in 810 adult smokers across 17 clinical trial locations in the United States.
  • Additionally, Achieve recently announced completion of enrollment for its confirmatory Phase 3 ORCA-3 smoking cessation trial.

Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Fragile X syndrome, Forward-looking statement, National, Plasma, Doctor of Philosophy, Neurodegeneration, Regeneration, Research, Private Securities Litigation Reform Act, Population, Neuron, MD, Brain, SAD, Safety, Neuroprotection, National Institute, NIA, Ageing, Georgetown University, Patient, National Institute on Aging, CNS, Pharmaceutical industry

The primary goal of this trial was to assess the safety and tolerability of oral NNI-362 in healthy aged subjects.

Key Points: 
  • The primary goal of this trial was to assess the safety and tolerability of oral NNI-362 in healthy aged subjects.
  • Dr. R. Scott Turner, MD, PhD, director of the Memory Disorders Program, Georgetown University, will be presenting this data at CTAD 2022 as one of the accepted late-breaking posters.
  • Alzheimers is a disease of aging, the greatest risk-factor, but there is not a single therapy available to halt or reverse this chronic neurodegenerative disorder.
  • This ability supports the drugs use to halt and reverse Alzheimers disease and other age-related neurodegenerative disorders.

FuelPositive Enters Final Phase of Assembling and Validating First Farm-Ready Demonstration System – Milestone Update: Hydrogen Purity Exceeds Expectations

Retrieved on: 
Monday, November 7, 2022
GLOBE, Certification, Forward-looking statement, Carbon, Method, TSX Venture Exchange, Nitrogen, Chairperson, Leite, Temperature, Farmer, Bureau Veritas, Intention, Professional, Sale, Atmosphere, Capital expenditure, News, Gas, Water, Pressure, OPEX, Climate change, No, Time, National Institute, FAT, National Institute of Standards and Technology, Company, ISO/IEC 17025, Hydrogen, Accreditation, Ammonia, NH3, NIST, Agriculture, Renewable energy, Industrial gas, Cryptocurrency, Fertilizer, Risk management, Technology

Each component of the system will be tested and commissioned individually before the full system is turned on.

Key Points: 
  • Each component of the system will be tested and commissioned individually before the full system is turned on.
  • As FuelPositive considers and evaluates various methods and technologies to produce hydrogen for its systems, two electrolyser technologies are being utilized to make hydrogen in the initial demonstration system.
  • FuelPositive has confirmed the hydrogen purity utilizing its internal certified lab and Bureau Veritas has validated the testing performed by FuelPositive.
  • The purity of the hydrogen directly corresponds to the conversion rate of the ammonia synthesis system and its ability to convert the gases to ammonia.

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 8, 2022
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PTSD, Investor, Fibromyalgia, Private Securities Litigation Reform Act, Initiative, National, NMDA, Government budget balance, HEAL, U.S. Securities and Exchange Commission, OUD, Research and development, Yale School of Medicine, Opioid use disorder, Webcast, Research, Annual report, NIH, Clinician, Oxycodone, R, Connective tissue disease, Chronic pain, Addiction, Brain, National Institute on Drug Abuse, Safety, ID, DSM-5, National Institute, Pharmacokinetics, Form 10-K, Patient, Security (finance), Administration, Post-traumatic stress disorder, Central nervous system, Yale University, NIDA, COVID-19, Trial of the century, Medical imaging, Pharmaceutical industry, Risk management

The study will be administered by the Yale Interdisciplinary Stress Center through a research collaboration with Aptinyx.

Key Points: 
  • The study will be administered by the Yale Interdisciplinary Stress Center through a research collaboration with Aptinyx.
  • In August 2022, Aptinyx announced that the primary endpoint was not achieved in its Phase 2b study of NYX-2925 in patients with fibromyalgia.
  • Net Loss: Net loss was $15.3 million for the third quarter of 2022, compared to a net loss of $21.2 million for the third quarter of 2021.
  • ET to review its financial results and highlights for the third quarter of 2022 and subsequent period.

Maudey™ Receives Innovator Award for Delivery of Remote Hearing Aid Education and Care

Retrieved on: 
Wednesday, November 9, 2022
Organization, Patient, National Institute, Ageing, National Institute on Aging, Method, Clinical trial, OTC, Life, Audiology, Small Business Innovation Research, IEEE Medal for Innovations in Healthcare Technology, HTM, LLC, Education, View, Efficiency, SBIR, Hearing, Multimedia, CEO, Pharmaceutical industry

FREDERICKSBURG, Va., Nov. 9, 2022 /PRNewswire/ -- Healthcare Technologies and Methods, LLC (HTM) announced today that it has been recognized for its Maudey hearing aid education and communication system in the third annual Hearing Technology Innovator Awards.Maudey won this prestigious award in the "Remote Care"category.

Key Points: 
  • FREDERICKSBURG, Va., Nov. 9, 2022 /PRNewswire/ -- Healthcare Technologies and Methods, LLC (HTM) announced today that it has been recognized for its Maudey hearing aid education and communication system in the third annual Hearing Technology Innovator Awards.Maudey won this prestigious award in the "Remote Care"category.
  • HTM's co-founder, President and CEO, Alan Letzt explained, "Maudey will simplify and enrichconsumers' hearing aid journey with its engaging, patient-centered videos and other tele-audiology features.
  • Through its annualHearing Technology Innovator Awards program, Hearing Health & Technology Matters (HHTM) recognizes technological innovations and achievements in the hearing industry.
  • "The goal of the Hearing Technology Innovator Awards is to recognize the organizations and people who bring new hearing care ideas to life," said the 2022 Awards Program Chair, Jerry DeRosa.

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Retrieved on: 
Tuesday, November 8, 2022
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Erythropoietin, B cell, Harvard University, Felicis Ventures, Proteomics, Myotonic dystrophy, Engineering, FDA, DeepMind, Horizon, Foundation for the National Institutes of Health, VC, University of California, Berkeley, Horizons Ventures, Insulin, Growth hormone, Systems biology, Venture capital, Series A round, Impossible Foods, Regenerative medicine, National Institute, Biomarker, Drug discovery, Intersection, California Institute for Regenerative Medicine, Stanford University, Regeneration, Doctor of Philosophy, Ageing, Investment, Protein, Protein engineering, Biology, Degenerative disease, California Institute for Quantitative Biosciences, Therapy, SVP, Compound, Siri, Map, Mubadala Investment Company, Pharmaceutical industry, Vaccine, Spotify

The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.

Key Points: 
  • The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.
  • Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease.
  • These limitations have constrained biopharmas approach to studying the role of secreted proteins only as drug targets or biomarkers, rather than drug agents themselves.
  • Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins.

Blue Earth Therapeutics Awarded UK MHRA Innovation Passport for Investigational 177Lu-rhPSMA-10.1 for Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PET, Acquisition, Magnetic resonance, Patient, Company, CEUS, Wales, Nuclear medicine, National Institute, Precision medicine, Health care, Google Images, Innovation, Biotechnology, Cancer, Isotope, Cardiac catheterization, Interventional radiology, Man, Therapeutic index, PSMA, Healthcare Improvement Scotland, SMC, Prostate cancer, Partnership, NICE, Institute of technology, 3D ultrasound, National Institute for Health and Care Excellence, MRI, Solution, MHRA, MAA, TDP, Magnetic resonance imaging, Therapy, Pharmaceutical industry, Medical imaging, Bracco

Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that its investigational therapeutic radiopharmaceutical, 177Lu-rhPSMA-10.1, has been awarded an Innovation Passport for the treatment of metastatic castrate-resistant prostate cancer.

Key Points: 
  • Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced that its investigational therapeutic radiopharmaceutical, 177Lu-rhPSMA-10.1, has been awarded an Innovation Passport for the treatment of metastatic castrate-resistant prostate cancer.
  • Blue Earth Therapeutics and Blue Earth Diagnostics work closely on the development of 177Lu-rhPSMA-10.1.
  • Blue Earth Therapeutics has an emerging pipeline, initially focused on prostate cancer, and with plans to expand into additional disease areas in oncology.
  • In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies.

Waterfall Asset Management Announces Appointment of Patrick Lo and Brian Rebello as Co-Chief Investment Officers

Retrieved on: 
Wednesday, November 9, 2022
MBA, Citigroup Global Markets Japan, RC, Industry, National Institute, NYSE, ABS, Massachusetts Institute of Technology, Company, Aberdeen Asset Management, CIO, Miami University, BS, Chemical engineering, CFA, Chief investment officer, National Institute of Technology, Tiruchirappalli, DWS Group, Financial services

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Waterfall Asset Management today announced that Patrick Lo and Brian Rebello have been elevated to Co-Chief Investment Officers.

Key Points: 
  • NEW YORK, Nov. 9, 2022 /PRNewswire/ -- Waterfall Asset Management today announced that Patrick Lo and Brian Rebello have been elevated to Co-Chief Investment Officers.
  • "Patrick and Brian have played key roles in Waterfall's investment efforts and overall evolution since each joined the Firm in its early days," said TomCapasse, founder and managing partner of Waterfall.
  • Prior to joining Waterfall in 2010, Brian was a portfolio manager at Aberdeen Asset Management.
  • Waterfall Asset Management is a global alternative investment manager focused on specialty finance opportunities within asset-backed credit, whole loans, real assets, and private equity.